Markets:

Overview

News

Currencies

International

Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

55.05 +0.36 (+0.65%)

Streaming Delayed Price Updated: 1:15 PM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

October 16, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Declares Fourth Quarter 2024 Dividend

October 11, 2024

From Royalty Pharma plc

Via GlobeNewswire

Peering Into Royalty Pharma's Recent Short Interest ↗

October 08, 2024

Via Benzinga

2 No-Brainer Dividend Stocks to Buy With $100 in October ↗

October 01, 2024

With their high yields and strong underlying businesses, these stocks are hard to pass up.

Via The Motley Fool

2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now? ↗

September 28, 2024

These dividend-paying stocks offer hard-to-find high yields, but that doesn't necessarily make them good stocks to buy now.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 18, 2024

Via Benzinga

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade ↗

September 16, 2024

Now could be a great time to scoop up three stocks trading way below their previous peaks.

Via The Motley Fool

2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗

September 08, 2024

These dividend payers could more than double their payouts in the decade ahead.

Via The Motley Fool

Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut ↗

September 04, 2024

Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company...

Via Benzinga

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

September 03, 2024

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference

August 28, 2024

From Royalty Pharma plc

Via GlobeNewswire

Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation' ↗

August 16, 2024

Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round."

Via Benzinga

RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Royalty Pharma Reports Second Quarter 2024 Results

August 08, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

July 24, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024

July 19, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Declares Third Quarter 2024 Dividend

July 17, 2024

From Royalty Pharma plc

Via GlobeNewswire

Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? ↗

July 11, 2024

CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.

Via Investor's Business Daily

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗

June 26, 2024

Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.

Via InvestorPlace

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 12, 2024

Via Benzinga

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 04, 2024

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes

June 03, 2024

From Royalty Pharma plc

Via GlobeNewswire

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗

May 28, 2024

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval.

Via Benzinga

Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗

May 28, 2024

The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug.

Via Investor's Business Daily

Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million

May 28, 2024

From Royalty Pharma plc

Via GlobeNewswire

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe ↗

May 23, 2024

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

Via Benzinga

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22, 2024

From Royalty Pharma plc; Cytokinetics

Via GlobeNewswire

7 Dividend Stocks to Buy at a 52-Week Low ↗

May 20, 2024

For steady yields, not to mention rebound potential, consider the following seven dividend stocks at a 52-week low.

Via InvestorPlace

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.